Side-by-side · Research reference

GHRP-2vsN-Acetyl Epitalon Amidate

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED15/42 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

01Mechanism of Action

Parameter

GHRP-2

N-Acetyl Epitalon Amidate

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

Downstream effect

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Feedback intact?

Yes, with somatostatin feedback active

—

Origin

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Antibody development

—

02Dosage Protocols

Parameter

GHRP-2

N-Acetyl Epitalon Amidate

Standard dose

100–300 mcg per injectionBowers 1990

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

Frequency

1–3× per day

Not specified in candidate papers

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 2 + clinical diagnostic useBowers 1990

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Duration

8–12 weeks on / 4 off (anecdotal)

Chronic treatment in aging culture

Sustained effect through late passages.

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

—

Half-life

~30 minMalagón 1999

—

Cell culture protocol

—

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

Modification stability

—

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

04Side Effects & Safety

Parameter

GHRP-2

N-Acetyl Epitalon Amidate

Cortisol elevation

Mild but measurableBowers 1990

—

Prolactin elevation

Mild but measurable

—

Hunger

Strong appetite increase

—

Injection site reaction

Mild erythema

—

IGF-1 elevation

Strong; monitor with chronic high-dose use

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Human safety data

—

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

Theoretical telomerase risk

—

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

In vitro observations

—

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

Absolute Contraindications

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Relative Contraindications

GHRP-2

·Untreated diabetes

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

05Administration Protocol

Parameter

GHRP-2

N-Acetyl Epitalon Amidate

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

3. Timing

Pre-sleep + fasted preferred.

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration